What comes next in medicine is shaped by the progress we’re making today. During our Investor Day, we shared updates on our corporate, clinical and commercial progress toward potentially delivering new treatment options for patients: ir.newamsterdampharma.com/news-release...

We know that innovation happens when scientific insight, conviction and execution come together to address patient needs. This is why we look forward to sharing key highlights about our progress during our Investor Day on August 5. Learn more and register for the webcast: bit.ly/4wwhDL1

CHMP has issued a positive opinion – recommending marketing authorization for our investigational therapy in primary hypercholesterolemia or mixed dyslipidemia, a step forward for people living with cardiovascular disease and other lipid-related conditions. Learn more: bit.ly/3TBDamK

Alzheimer’s research continues to evolve as we learn more about factors tied to disease risk and prevention. At AAIC 2026, we’ll share research exploring the link between heart and brain health and potential upstream approaches to Alzheimer’s prevention. Learn more: bit.ly/4vaxsp9

Cardiovascular risk doesn’t look the same for every patient, and the approach to managing it shouldn’t either. We’re sharing data at #NLASessions 2026 to advance how lipid management and cardiovascular risk are being understood and addressed. Learn more: ir.newamsterdampharma.com/news-release...

Advancing cardiovascular care means continuing to address the needs of patients who remain at risk despite existing treatment options. Addressing this unmet need is an opportunity we’re committed to — and one we’re excited to discuss at the Goldman Sachs 47th Annual Global Healthcare Conference.

We are participating in two investor conferences this May: The Bank of America Securities 2026 Health Care Conference on May 12 and the 2026 RBC Capital Market’s Global Healthcare Conference on May 20. For more details on our presence and live webcast, read the full press release: bit.ly/42qqn82

Even with LDL‑C at goal, residual cardiovascular risk may remain for people living with ASCVD due to other contributing risk factors, making comprehensive risk reduction and ongoing care essential. Learn more about LDL-C and cardiovascular risk in ASCVD: www.expectmoreforldl.com/ascvd-risk/

We’re excited to join the cardiovascular community at the @American College of Cardiology Annual Scientific Sessions. Stop by our booth (1209) to connect with us and learn more about cardiometabolic-related residual risk and other lipid-related conditions. Hope to see you there. #ACC26

We’re presenting new data at #ACC26 from our Phase 3 clinical trials and additional findings for cardiovascular disease and other lipid-related conditions. Learn more: www.globenewswire.com/news-release...

Cholesterol metabolism supports brain function and is increasingly being studied for its role in Alzheimer’s disease, especially in people who carry the APOE4 gene. Our #sponsored Nature article explores how these pathways may enable earlier, prevention-focused intervention. bit.ly/3PICdHg

Our leadership team will be at several conferences in March to discuss how we’re working to advance innovative therapies for cardiovascular disease (CVD) and other lipid-related conditions. Learn more about how to watch the presentations live or view the archived replays afterward: bit.ly/4slb5ML

🔓NEW in @natmed.nature.com: Review the data from our BROOKLYN Phase 3 clinical trial, which evaluated our investigational CETP inhibitor in patients with heterozygous familial hypercholesterolemia on top of maximum tolerated lipid-lowering therapies. www.newamsterdampharma.com/wp-content/u...

We’re on a mission to change the landscape of lipid-lowering treatment. By advancing innovative therapies for CVD and other lipid-related conditions, we aim to empower people to better manage their health and reduce the likelihood of serious complications. www.newamsterdampharma.com

Alzheimer’s and Dementia Care Education Week is a timely reminder that understanding and managing lipids may support long-term brain health and overall well-being. Learn more about the connection between lipids and Alzheimer’s disease: www.newamsterdampharma.com/lipid-relate...

As estrogen declines during menopause, cardiovascular risk rises. On Wear Red Day, learn how routine monitoring and LDL-C lowering strategies can support better long-term outcomes. Learn more: www.newamsterdampharma.com/our-focus/

Atherosclerosis develops quietly, long before symptoms appear. Listen as Prof. Kausik Ray explains why caring for your blood vessels today can prevent urgent problems tomorrow. Learn more about cardiovascular risk factors: bit.ly/4t6kZmu

Research suggests that sustaining lower LDL-C over time may delay ASCVD events by decades. The impact of long-term prevention can be profound, and the opportunity to improve outcomes is clear. www.expectmoreforldl.com/ldl-c-goals-...

Drs. Alan Brown and Michael Davidson explain why addressing LDL-C from an early age can have a profound impact on long-term cardiovascular health. Learn more about LDL-C goals, guidelines, and treatment strategies: www.expectmoreforldl.com/ldl-c-goals-...

We showcased our Phase 3 CETP inhibitor data at multiple major conferences and published findings in top-tier journals throughout 2025. With strong momentum, 2026 is shaping up to be another landmark year. Explore our strategic priorities for the year ahead: ir.newamsterdampharma.com/news-release...

Low rates of Lp(a) testing mean many patients miss opportunities to address residual cardiovascular risk. A JAHA study found that testing for Lp(a) is linked to greater initiation of lipid-lowering therapy. Learn more about residual risk factors: www.expectmoreforldl.com/ldl-c-and-be...

Happy New Year from all of us at NewAmsterdam Pharma! We’re excited for what 2026 has in store, particularly as we continue to advance PREVAIL, our Phase 3 cardiovascular outcomes trial. The stage is set for another year of progress!

Happy holidays and best wishes for a healthy and joyful New Year from all of us at NewAmsterdam Pharma! As we look ahead to 2026, we remain committed to advancing our lead investigational asset and exploring new ways to address the global impact of cardiovascular disease.

Cholesterol isn’t just important for heart health—it’s also vital for the brain. ApoE-bound lipoproteins move cholesterol to the cells that depend on it—making it central to understanding the connection between cholesterol and Alzheimer’s disease. www.newamsterdampharma.com/lipid-relate...

Taking charge of your heart health is a team effort. Clinical recommendations guide treatment, but your actions make the difference. Learn more about preventing heart disease from @americanheart.bsky.social: www.heart.org/en/healthy-l...

Lp(a) isn’t as well-known as LDL-C, but high levels can sharply increase the risk of heart attacks and strokes—even in people with normal LDL. This recent @washingtonpost.com article explores Lp(a), its genetic roots, and why it’s gaining attention. wapo.st/48vKTaV

A recent study found only ~40% of ASCVD patients achieved guideline-recommended LDL-C targets, highlighting the need for frequent follow-up, patient counseling, and combination therapies. Learn more about the unmet need in cardiovascular disease: www.newamsterdampharma.com/unmet-need-c...

About 1 in 9 adults worldwide are living with diabetes, and the diagnosis doubles the risk for heart disease. People with type 2 diabetes have a similar risk of CVD as those who already have it. This #WorldDiabetesDay, learn more about our research: www.newamsterdampharma.com/lipid-relate...

Lowering LDL-C is essential for cardiovascular risk reduction, but it’s not enough on its own. Our CEO Dr. Michael Davidson details why the future of hyperlipidemia management needs to go beyond LDL-C. bit.ly/3LAQSCA

Happening now at #AHA25: José Inia leads a digital poster presentation on a preclinical analysis evaluating a combination approach to targeting atherosclerotic plaque lesions. Review the abstract to learn more about our investigational CETP inhibitor: eppro02.ativ.me//web/index.p...